Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 6 months ago

Prevention & Chronic Conditions
Cardiovascular Disease and Type 2 Diabetes
Author(s): Martin Berger , Nikolaus Marx , Katharina Marx-Schütt Added: 2 months ago

Cardiovascular Renal Metabolic

Prevention & Chronic Conditions
Cardiovascular Risk in NAFLD
Author(s): Paula Luque-Linero , Jose M Guerra Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Apabetalone: Evidence and Outcomes Related to Cardiovascular Health
Author(s): Yimeng Zhang , Nimai Desai , Derek Connolly Added: 4 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Cardiovascular Disease and COVID-19 Vaccines
Author(s): Abdulrhman Khaity , Ala’ Abdala Mohamad Rababah , Omar A Abdelwahab , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
Insights in Cardiovascular Innovation and Research
Author(s): Michael C Gibson , Dipti Itchhaporia Added: 8 months ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia, former president of the ACC, is joined by Dr C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024.Dr Itchhaporia and Dr Gibson explore strategies to enhance efficiency in cardiovascular… View more

Electrophysiology & Arrhythmia

Digital Health
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 11 months ago

COVID-19

CV Disease in Special Populations
FLOW: Kidney, Cardiovascular, Mortality, Metabolic and Safety Results
Author(s): Richard Pratley Added: 10 months ago
EASD 24 - We are joined by Dr Richard Pratley (AdventHealth Diabetes Institute, US) to discuss the kidney, cardiovascular, metabolic, mortality and safety results from the FLOW trial.Interview Questions:1. What is the reasoning behind the FLOW Trial?2. What was the patient population and study design?3. What are the key results?4. Were there any surprising or unexpected findings?5. What further… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
Value Creation Through AI and Cardiovascular Imaging
Author(s): David Playford , Kate Hanneman Added: 1 year ago
In this video, Dr Kate Hanneman (University of Toronto, CA) and Prof David Playford (Hollywood Private Hospital, AU) sit down to discuss the main talking points raised by the recent AHA scientific statement, "Value Creation Through Artificial Intelligence and Cardiovascular Imaging".Recorded remotely from Toronto and Nedlands, 2024.Editor: Jordan RanceVideo Specialist: Dan Brent View more

Digital Health
NF-kB in Cardiovascular Disease
Author(s): Akira Matsumori Added: 2 years ago

Vascular Disease and Surgery

Imaging & Diagnostics